Clinical Trials /

Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

NCT04230759

Description:

The RADIANCE multicenter, randomized phase II trial will assess the efficacy of durvalumab, a PD-L1 immune checkpoint inhibitor, in combination with primary mitomycin C (MMC)/5-fluorouracil (5-FU)-based radiochemotherapy (RCT) in patients with locally-advanced anal squamous cell carcinoma (ASCC).

Related Conditions:
  • Anal Canal Squamous Cell Carcinoma
  • Anal Margin Squamous Cell Carcinoma
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group
  • Official Title: Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.

Clinical Trial IDs

  • ORG STUDY ID: RADIANCE
  • SECONDARY ID: 2018-003005-25
  • SECONDARY ID: 70113615
  • SECONDARY ID: ESR-17-13077
  • NCT ID: NCT04230759

Conditions

  • Anal Cancer
  • Anal Carcinoma
  • Anal Cancer Stage III
  • Anal Cancer Stage II

Interventions

DrugSynonymsArms
Chemotherapyall brands of 5-fluorouracil (5-FU) are allowed, all brands of Mitomycin C (MMC) are allowed5FU+Mitomycin C
DurvalumabPD-L1 inhibitor5FU+Mitomycin C+Durvalumab

Purpose

The RADIANCE multicenter, randomized phase II trial will assess the efficacy of durvalumab, a PD-L1 immune checkpoint inhibitor, in combination with primary mitomycin C (MMC)/5-fluorouracil (5-FU)-based radiochemotherapy (RCT) in patients with locally-advanced anal squamous cell carcinoma (ASCC).

Detailed Description

      Anal squamous cell carcinomas (ASCC) are increasing in frequency across the developed world.
      There is a strong rationale for combining the PD-L1 immune checkpoint inhibitor durvalumab
      with radiochemotherapy (RCT) in patients with ASCC. First, although primary RCT with
      concurrent mitomycin C and 5-fluorouracil (MMC/5-FU) is the standard treatment for ASCC, the
      3-year DFS in patients with locally-advanced disease is only in the range of 60%. Second,
      approximately 80-90% of patients with ASCC are human papilloma virus (HPV)-positive, which is
      associated with higher tumor "immunogenicity" in this malignancy that is known to correlate
      with better response to RCT as well as PD-1/PD-L1 immune checkpoint inhibitors. Also, PD-L1
      expression was observed in 33%-62% of patients with locally advanced non-metastatic ASCC that
      correlated with tumor stage. Third, inhibition of the PD-1/PD-L1 axis showed encouraging
      responses in recurrent/metastatic ASCC in two phase Ib/II trials. Fourth, several data
      indicate complementary roles between R(C)T and immunotherapy. Fifth, R(C)T can induce PD-L1
      upregulation with resulting dysfunction in CD8+ T-cells, and addition of anti-PD-L1 to R(C)T
      can overcome T-cell suppression to reinvigorate immune surveillance. First clinical studies
      have demonstrated promising findings for the combination of RCT and immunotherapies. Thus,
      based on the above data, RCT combined with durvalumab is expected to be more effective than
      primary RCT alone. Altogether, the hereby proposed RADIANCE multicenter, randomized phase II
      trial aims to improve the current standard treatment by incorporating durvalumab to the
      primary MMC/5-FU-based RCT in patients with locally-advanced ASCC (T2=>4cm Nany, stage
      IIB-IIIC).
    

Trial Arms

NameTypeDescriptionInterventions
5FU+Mitomycin CActive ComparatorRadiochemotherapy for anal cancer
  • Chemotherapy
5FU+Mitomycin C+DurvalumabExperimentalRadiochemotherapy with Durvalumab for anal cancer
  • Chemotherapy
  • Durvalumab

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically-confirmed ASCC (both genders) of the anal canal or the anal margin

          -  UICC-Stage IIB-IIIC including T2>4cm Nany (IIB: T3N0M0; IIIA: T1-2N1M0; IIIB: T4N0M0;
             IIIC: T3-4N1M0; T2>4cm Nany) according to proctoscopy, pelvic MRI, CT scan of thorax
             and abdomen, all within 30 days prior to recruitment

          -  Age ≥ 18 years, no upper age limit

          -  ECOG-Performance score 0-1

          -  History/physical examination within 30 days prior to recruitment

          -  Written informed consent and any locally-required authorization (e.g. EU Data Privacy
             Directive in the EU) obtained from the patient prior to performing any
             protocol-related procedures, including screening evaluations

          -  Life expectancy of > 12 months

          -  Body weight >30kg

          -  Hemoglobin ≥9.0 g/dl

          -  Leukocytes >3.5 x 10 ^9/l

          -  Absolute neutrophil count (ANC) 1.5 x 10 9/l (> 1500 per mm3)

          -  Platelet count ≥100 x 109/l (>100,000 per mm3)

          -  Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN). (This will not apply
             to patients with confirmed Gilbert's syndrome (persistent or recurrent
             hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or
             hepatic pathology), who will be allowed only in consultation with their physician.

          -  AST (SGOT), ALT (SGPT), AP ≤ 3x institutional ULN

          -  Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula creatinine clearance

          -  Female subject of childbearing potential should have a negative serum pregnancy within
             72 hours prior to receiving the first dose of durvalumab. A highly sensitive pregnancy
             test must be used.

          -  Female subjects of childbearing potential must be willing to use a highly effective
             contraceptive measure as defined in the Clinical Trial Facilitation Group (CTFG)
             guideline ("Recommendations related to contraception and pregnancy testing in clinical
             trials"). Highly effective contraception is required from screening to 90 days after
             the last dose of durvalumab. (Note: Abstinence is acceptable if this is the usual
             lifestyle and preferred contraception for the subject.)

          -  Male subjects of childbearing potential must agree to use a highly effective method of
             contraception, starting from screening to 90 days after the last dose of durvalumab.
             (Note: Abstinence is acceptable if this is the usual lifestyle and preferred
             contraception for the subject.) Male patients should refrain from fathering a child or
             donating sperm during the study and for 180 days after the last dose of durvalumab +
             any drug combination therapy or 90 days after the last dose of durvalumab monotherapy,
             whichever is the longer time period.

          -  Patient is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including follow
             up.

          -  For HIV-positive patients: running combined antiretroviral therapy (CART) on a stable
             dose at study entry and undetectable HIV-viral load (HIV Viral load <50 copies/mL and
             CD4>200/Mircoliter). Patients will be closely monitored and CART management will be
             performed according to appropriate labelling guidance of the antiviral therapy. CART
             should be on a stable dose at study entry.

        Exclusion Criteria:

          -  UICC-Stage I-IIA ASCC defined as cT1N0M0 or cT2 <4cm N0M0 disease

          -  Second malignancy other than basalioma or cervical/genital/ neoplasia in situ

          -  History of another primary malignancy except for:

               -  Malignancy treated with curative intent and with no known active disease ≥5 years
                  before the first dose of durvalumab and of low potential risk for recurrence

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease

               -  Adequately treated carcinoma in situ without evidence of disease

          -  Known DPD-deficiency

          -  Participation in another clinical study with an investigational product during the
             last 12 months

          -  Concurrent enrolment in another clinical study, unless it is an observational
             (non-interventional) clinical study or during the follow-up period of an
             interventional study

          -  Any previous treatment with other immunotherapy, a PD1 or PD-L1 inhibitor

          -  QT interval corrected for heart rate (QTc) ≥470 ms

          -  Current or prior use of immunosuppressive medication within 14 days before the first
             dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/d of
             prednisone, or an equivalent corticosteroid. In case of recent introduction of CART,
             inclusion will be possible provided subjects had at least 4 weeks of treatment prior
             to inclusion.

          -  Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion
             criteria:

               -  Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after
                  consultation with the Study Chairman.

               -  Patients with irreversible toxicity not reasonably expected to be exacerbated by
                  treatment with durvalumab may be included only after consultation with the Study
                  Chairman

          -  Any concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment, other
             than the study medication. Concurrent use of hormonal therapy for non-cancer-related
             conditions (e.g., hormone replacement therapy) is acceptable.

          -  Previous radiotherapy treatment to the pelvis or radiotherapy treatment to more than
             30% of the bone marrow or with a wide field of radiation within 4 weeks of the first
             dose of study drug

          -  Major surgical procedure (as defined by the Investigator) within 28 days prior to the
             first dose of durvalumab.

          -  History of allogenic organ transplantation.

          -  Active or prior documented autoimmune or inflammatory disorders (including
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid
             arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this
             criterion:

               -  Patients with vitiligo or alopecia

               -  Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on
                  hormone replacement

               -  Any chronic skin condition that does not require systemic therapy

               -  Patients without active disease in the last 5 years may be included but only
                  after consultation with the study chairman

               -  Patients with celiac disease controlled by diet alone

          -  Uncontrolled intercurrent illness, including but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic
             gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social
             situations that would limit compliance with study requirement, substantially increase
             risk of incurring AEs or compromise the ability of the patient to give written
             informed consent

          -  History of leptomeningeal carcinomatosis or any other metastatic disease

          -  History of active primary immunodeficiency

          -  Active infection including tuberculosis (clinical evaluation that includes clinical
             history, physical examination and radiographic findings, and TB testing in line with
             local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result),
             hepatitis C. Patients with a past or resolved HBV infection (defined as the presence
             of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients
             positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction
             is negative for HCV RNA.

          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of
             durvalumab. Note: Patients, if enrolled, should not receive live vaccine whilst
             receiving durvalumab and up to 30 days after the last dose of durvalumab.

          -  Known allergy or hypersensitivity to any of the study/investigational drugs or any of
             the study/investigational drug excipients and/or radiochemotherapy with 5-FU and
             Mitomycin C.

          -  Female patients who are pregnant or breastfeeding or male or female patients of
             reproductive potential who are not willing to employ effective birth control from
             screening to 90 days after the last dose of durvalumab.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Disease-free survival (DFS)
Time Frame:3 years
Safety Issue:
Description:DFS is defined as the time between randomization and the first of the following events: (a) non-complete clinical response at restaging MRI and proctoscopy, including biopsies of suspicious findings, 26 weeks after initiation of radiochemotherapy, (b) locoregional recurrence after initial complete clinical response (cCR), (c) distant metastases, (d) second primary cancer, or (e) death from any cause, whichever occurs first. Patients without any of these events are censored at the time point of last observation.

Secondary Outcome Measures

Measure:Major adverse events
Time Frame:3 Years
Safety Issue:
Description:Adverse events will be graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
Measure:cCR
Time Frame:26 weeks
Safety Issue:
Description:Complete clinical response rate assessed 26 weeks after initiation of radiochemotherapy
Measure:Overall survival
Time Frame:3 Years
Safety Issue:
Description:Overall survival defined as the time between randomization and death from any cause
Measure:Colostomy-free survival
Time Frame:3 Years
Safety Issue:
Description:Colostomy-free survival defined as time between randomization and a definitive colostomy for progression, relapse, or complication
Measure:Cumulative incidence of locoregional recurrence
Time Frame:3 Years
Safety Issue:
Description:Cumulative incidence of locoregional recurrence defined as the incidence of locoregional recurrence form the time of randomization
Measure:Cumulative incidence of distant recurrence
Time Frame:3 Years
Safety Issue:
Description:Cumulative incidence of distant recurrence defined as the incidence of distant recurrence form the time of randomization
Measure:Quality of life questionnaires
Time Frame:3 Years
Safety Issue:
Description:Quality of life questionnaire QLQ-C30
Measure:Quality of life questionnaires
Time Frame:3 Years
Safety Issue:
Description:Quality of life questionnaire QLQ-ANL27

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Goethe University

Trial Keywords

  • Anal Cancer
  • Anal Carcinoma
  • Durvalumab
  • PD-L1 immune checkpoint inhibitor

Last Updated

July 28, 2020